EGFR
EGFR (epidermal growth factor receptor) inhibitors are compounds that block the signaling of EGFR, a receptor that is often overexpressed in various cancers and plays a critical role in angiogenesis. EGFR inhibitors are used to prevent tumor growth and metastasis by disrupting the pathways that promote blood vessel formation in tumors. These inhibitors are widely used in cancer research and therapy. At CymitQuimica, we offer a diverse selection of high-quality EGFR inhibitors to support your research in oncology and angiogenesis.
Found 572 products of "EGFR"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Tarlox-TKI
CAS:<p>Tarlox-TKI (Kinase inhibitor-1) is a pan-ErbB inhibitor, the active ingredient of Tarloxotinib, which has antitumor activity.</p>Formula:C19H18BrClN6OPurity:97.03%Color and Shape:SolidMolecular weight:461.74EGFR-IN-69
CAS:<p>EGFR-IN-69: Potent EGFR inhibitor for NSCLC research; IC50: 4.3-25.6 nM against various EGFR mutations.</p>Formula:C31H37Cl2N7O3SColor and Shape:SolidMolecular weight:658.64EGFR-IN-67
CAS:<p>EGFR-IN-67 (Compound 7d) is a potent inhibitor of EGFR with anticancer activity (IC 50 = 0.34 μM) [1].</p>Formula:C18H17N3SColor and Shape:SolidMolecular weight:307.41EGFR-IN-54
CAS:<p>EGFR-IN-54 (Compound 3c) is a potent inhibitor of EGFR (IC50: 1.623 μM) and is toxic to cancer cells.</p>Formula:C17H14N4O4S3Color and Shape:SolidMolecular weight:434.51EGFR-IN-21
CAS:<p>EGFR-IN-21, a potent EGFR inhibitor, exhibits an IC50 of 0.38 nM, demonstrating significant antitumor activity.</p>Formula:C36H44BrN10O2PColor and Shape:SolidMolecular weight:759.68NSC81111
CAS:<p>NSC81111 shows anticaner effects which is a potent and orally active inhibitor of EGFR-TK (IC50 = 0.15 nM) [1].</p>Formula:C19H16O4Color and Shape:SolidMolecular weight:308.33EGFR-IN-73
CAS:<p>EGFR-IN-73 (Compound 3f) effectively inhibits the prevalent EGFR mutation, EGFR Del19, exhibiting an IC50 value of 119 nM [1].</p>Formula:C19H17ClFN3O4Purity:98%Color and Shape:SolidMolecular weight:405.81Antiproliferative agent-34
CAS:<p>Antiproliferative Agent-34 (Compound A14), a multitarget kinase inhibitor, demonstrates IC50 values of 177 nM for EGFR L858R/T790M and 1567 nM for EGFR WT.</p>Formula:C27H27N7O5Purity:98%Color and Shape:SolidMolecular weight:529.55EGFR-IN-89
CAS:<p>EGFR-IN-89 (compound 13k) is a fourth-generation inhibitor selectively targeting EGFR mutations, exhibiting potent activity with an IC50 of 10.1 nM against</p>Formula:C26H31FN8O2SPurity:98%Color and Shape:SolidMolecular weight:538.64AG-183
CAS:<p>(Z)-Tyrphostin A51, a Z-isomer of Lanoconazole A51, is a strong PTK inhibitor blocking [3 H]taurine release and tyrosyl phosphorylation.</p>Formula:C13H8N4O3Color and Shape:Brown SolidMolecular weight:268.23EGFR-IN-16
CAS:<p>EGFR-IN-16 (AG473) is an inhibitor of EGFR in human A431 cells.</p>Formula:C16H11NO3Purity:98%Color and Shape:SolidMolecular weight:265.26(E/Z)-AG490
CAS:<p>(E/Z)-AG490 is a racemic mix of (E)- and (Z)-isomers; it inhibits tyrosine kinase, EGFR, Stat-3, and JAK2/3.</p>Formula:C17H14N2O3Color and Shape:SolidMolecular weight:294.3EGFR-IN-75
<p>EGFR-IN-75 inhibits EGFR WT/T790M; IC50s: 0.28/5.02 μM. It has anticancer and antioxidant effects.</p>Formula:C10H6N6S2Color and Shape:SolidMolecular weight:274.32CGP52411
CAS:<p>CGP52411 is an orally active, and ATP-competitive inhibitor of EGFR (IC50: 0.3 μM).</p>Formula:C20H15N3O2Purity:99.78%Color and Shape:SolidMolecular weight:329.35EGFR-IN-50
CAS:<p>EGFR-IN-50, a potent EGFR blocker, hinders L858R mutation; GI50: 8 nM for TEL-EGFR-L858R, 6.03 μM for T790M-L858R; curbs cancer cell growth.</p>Formula:C24H26BrN3O4S2Color and Shape:SolidMolecular weight:564.51EGFR-IN-53
CAS:<p>EGFR-IN-53 (Compound 7) is a potent inhibitor of EGFR (IC50 = 8.264 μM) that exhibits cytotoxic activity against cancer cell lines [1].</p>Formula:C14H13N3O2SColor and Shape:SolidMolecular weight:287.34EGFR-IN-28
CAS:<p>EGFR-IN-28 is a potent EGFR inhibitor. EGFR-IN-28 has antitumor activity .</p>Formula:C31H39BrN10O3SColor and Shape:SolidMolecular weight:711.68NSC114126
CAS:<p>NSC114126 is a potent, oral EGFR-TK inhibitor with strong antiproliferative effects, promising for cancer research.</p>Formula:C22H20O4Color and Shape:SolidMolecular weight:348.39BAY 2476568
CAS:<p>BAY 2476568 is a selective and potent EGFR inhibitor that acts on both wild-type EGFR (IC50 <0.2 nM) and mutant EGFR (IC50 <0.2 nM).</p>Formula:C24H27FN4O4Color and Shape:SolidMolecular weight:454.49LDC0496
CAS:<p>LDC0496: Potent EGFR/Her2 exon 20 inhibitor; selective for wild-type EGFR, kinase-specific.</p>Formula:C32H35N5O3Color and Shape:SolidMolecular weight:537.65Lavendustin C6
CAS:<p>Lavendustin C6 is a effective tyrosine kinase inhibitor.</p>Formula:C20H25NO5Color and Shape:SolidMolecular weight:359.42PDZ1i
CAS:<p>PDZ1i: potent MDA-9/Syntenin inhibitor; crosses blood-brain barrier; targets GBM, FAK, EGFRvIII; lowers MMP secretion.</p>Formula:C28H26N8O4Color and Shape:SolidMolecular weight:538.56Nazartinib mesylate
CAS:<p>Nazartinib mesylate is a novel, covalent mutant-selective inhibitor of EGFR (Ki and Kinact: 31 nM and 0.222/min on EGFR(L858R/790M) mutant).</p>Formula:C27H35ClN6O5SPurity:98%Color and Shape:SolidMolecular weight:591.12Tyrphostin AG 112
CAS:<p>Tyrphostin AG 112 is an inhibitor of EGFR phosphorylation.</p>Formula:C13H8N4OPurity:97.01%Color and Shape:SolidMolecular weight:236.23DBPR112
CAS:<p>DBPR112: oral furanopyrimidine EGFR inhibitor; IC50: 15 nM (EGFRWT), 48 nM (L858R/T790M); blocks ATP site, strong antitumor effects.</p>Formula:C32H31N5O3Purity:99.25%Color and Shape:SolidMolecular weight:533.62Epertinib
CAS:<p>Epertinib is a reversible and selective tyrosine kinase inhibitor of EGFR, HER2, and HER4 (IC50s: 1.48 nM, 7.15 nM, and 2.49 nM).</p>Formula:C30H27ClFN5O3Purity:98%Color and Shape:SolidMolecular weight:560.02MS 39
CAS:<p>MS 39, a selective EGFR depressant, degrades mutant receptors in lung cancer lines without affecting wild-type. Effective in vitro and in mice.</p>Formula:C55H71ClFN9O7SColor and Shape:SolidMolecular weight:1056.72RTC-5
CAS:<p>RTC-5 (TRC-382) is a phenothiazine compound that has been specifically enhanced for its potent anti-cancer properties.</p>Formula:C24H22ClF3N2O3SPurity:98.14%Color and Shape:SolidMolecular weight:510.96SDZ281-977
CAS:<p>SDZ 281-977 is a derivative of Lavendustin A which is the EGF receptor tyrosine kinase inhibitor.</p>Formula:C18H20O5Purity:99.64%Color and Shape:SolidMolecular weight:316.35EGFR-IN-2
CAS:<p>EGFR-IN-2 is a oral and mutation-selective EGFR inhibito,NSCLC, with high selectivity for resistant single and double mutant T790M.</p>Formula:C26H33N9O3SPurity:98.52% - 99.79%Color and Shape:SolidMolecular weight:551.66Gefitinib N-oxide
CAS:<p>Gefitinib is an EGFR tyrosine kinase inhibitor, with IC50 of 2-37 nM in NR6wtEGFR cells. Gefitinib N-oxide is the N-oxide derivative of Gefitinib.</p>Formula:C22H24ClFN4O4Purity:98%Color and Shape:SolidMolecular weight:462.9Nimotuzumab
CAS:<p>Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).</p>Purity:95.00% - 98.5% (SDS-PAGE); 96.4% (SEC-HPLC)Color and Shape:LiquidEGFR-IN-5
CAS:<p>EGFR-IN-5 inhibits EGFR & mutants; IC50: EGFR 10.4nM, L858R 1.1nM, L858R/T790M 34nM, L858R/T790M/C797S 7.2nM.</p>Formula:C31H38FN9OPurity:98.17%Color and Shape:SolidMolecular weight:571.69BKI-1369
CAS:<p>BKI-1369 is a bumped kinase inhibitor. BKI-1369 increases hERG-inhibitory activity (IC50:1.52 μM).</p>Formula:C23H27N7OColor and Shape:SolidMolecular weight:417.51EGFR-IN-68
CAS:<p>EGFR-IN-68, an EGFR inhibitor, has an IC50 of 0.33 μM and shows significant anticancer effects.</p>Formula:C24H22N2OColor and Shape:SolidMolecular weight:354.44JBJ-04-125-02
CAS:<p>JBJ-04-125-02: Oral EGFR inhibitor, targets EGFRL858R/T790M with 0.26 nM IC50, halts cancer growth, anti-tumor.</p>Formula:C29H26FN5O3SPurity:98%Color and Shape:SolidMolecular weight:543.61EGFR mutant-IN-2
CAS:<p>EGFR mutant-IN-2 (Compound D51) is an inhibitor of EGFR mutants, specifically targeting EGFR L858R/T790M/C797S and EGFR del19/T790M/C797S mutants with IC50 values of 14 nM and 62 nM, respectively. This compound exhibits favorable pharmacokinetic (PK) parameters, safety properties, in vivo stability, and demonstrates antitumor activity [1].</p>Formula:C27H27F3N6O2SColor and Shape:SolidMolecular weight:556.6Mutated EGFR-IN-2
CAS:<p>Mutated EGFR-IN-2 is an inhibitor of mutant-selective EGFR.</p>Formula:C29H35FN8O3Purity:98%Color and Shape:SolidMolecular weight:562.64GW 583340 dihydrochloride
CAS:<p>GW 583340 dihydrochloride is a potent and orally available dual EGFR/ErbB2 inhibitor and inhibits 80% of tumor growth in a mouse xenograft mode.</p>Formula:C28H27Cl3FN5O3S2Purity:98.80%Color and Shape:SolidMolecular weight:671.03EGFR-IN-64
CAS:<p>EGFR-IN-64 inhibits EGFR with 0.33 μM IC50, showing promising anticancer properties.</p>Formula:C20H21N3O3Color and Shape:SolidMolecular weight:351.4JNJ28871063 hydrochloride
CAS:<p>ErbB receptor family inhibitor</p>Formula:C24H28Cl2N6O3Purity:98%Color and Shape:SolidMolecular weight:519.42Mutated EGFR-IN-3
CAS:<p>Mutated EGFR-IN-3: ATP-competitive, selective dibenzodiazepinone inhibitor for EGFR mutations, IC50 12-13 nM.</p>Formula:C31H29FN4O2Purity:98%Color and Shape:SolidMolecular weight:508.59EMI48
CAS:<p>EMI48, a derivative of EMI1, exhibits increased efficacy against mutant EGFR compared to EMI1. It specifically inhibits EGFR triple mutants [1].</p>Formula:C21H20N2O3Color and Shape:SolidMolecular weight:348.4EGFR-IN-39
CAS:<p>EGFR-IN-39, an acrylamide, is a potent EGFR inhibitor and antitumor agent targeting NSCLC with low toxicity. See WO2021185348A1 for details.</p>Formula:C24H25ClN6O3Color and Shape:SolidMolecular weight:480.95Selatinib
CAS:<p>Selatinib is an orally active and potent dual inhibitor of EGFR and ErbB2 with anticancer activity that inhibits the growth of NCI-N87 tumor cells.</p>Formula:C29H26ClFN4O3SPurity:98.00%Color and Shape:SolidMolecular weight:565.06EMI56
CAS:<p>EMI56, a derivative of EMI1, exhibits enhanced potency against mutant EGFR compared to EMI1. Additionally, EMI56 effectively inhibits EGFR triple mutants[1].</p>Formula:C21H20N2O3Color and Shape:SolidMolecular weight:348.4EGFR-IN-55
CAS:<p>"EGFR-IN-55 targets EGFRWT (70 nM IC50) & EGFRL858R/T790M (3.9 nM IC50), halts NCI-H1975 cell cycle in G0/G1, showing anticancer properties."</p>Formula:C25H25Cl2N7O2Color and Shape:SolidMolecular weight:526.42EGFR-IN-49
CAS:<p>EGFR-IN-49 selectively inhibits EGFR mutations T790M (IC50: 65 nM) & T790M/L858R (IC50: 13.6 nM), triggering apoptosis dose-dependently.</p>Formula:C22H15N5O2SColor and Shape:SolidMolecular weight:413.45EGFR-IN-31
CAS:<p>EGFR-IN-31: Potent EGFR inhibitor, targets mutations & overexpression in NSCLC; potential cancer research compound. (WO2021185298A1, 2)</p>Formula:C32H36FN7O2Color and Shape:SolidMolecular weight:569.67EGFR/HER2-IN-3
CAS:<p>EGFR/HER2-IN-3 (Compound ZINC21942954) is a dual EGFR and HER2 inhibitor.</p>Formula:C26H23N5O3Color and Shape:SolidMolecular weight:453.49Tyrphostin 51
CAS:<p>Tyrphostin 51 is an effective inhibitor of EGFR kinase.</p>Formula:C13H8N4O3Purity:98%Color and Shape:SolidMolecular weight:268.23EGFR-IN-25
CAS:<p>EGFR-IN-25, an efficacious EGFR inhibitor, demonstrates IC50 values of 9 nM for BaF3 cells (EGFR DEL19/T790M/C797S) and 60 nM for A431 cells (WT), respectively.</p>Formula:C34H43N9O2Color and Shape:SolidMolecular weight:609.76MS 154N
CAS:<p>MS 154N is a negative control for MS 154, binds WT/L858R EGFR tightly (Kd 3-4.3nM), doesn't trigger mutant EGFR degradation.</p>Formula:C47H56ClFN8O8Color and Shape:SolidMolecular weight:915.45JBJ-09-063 hydrochloride
<p>JBJ-09-063 hydrochloride: targeted EGFR inhibitor, effective for various mutations and TKI-resistant lung cancer models.</p>Formula:C31H30ClFN4O3SColor and Shape:SolidMolecular weight:593.11PD 173955-Analog1
CAS:<p>PD 173955-Analog1 is a potent c-Src inhibitor known to have activity against a variety of cancers including colon, lung, head and neck carcinoma.</p>Formula:C21H14Cl2N4O3Color and Shape:SolidMolecular weight:441.27EGA
CAS:<p>EGA blocks the entry of a variety of other acid-dependent bacterial toxins and viruses into mammalian cells and can be used to treat infectious diseases.</p>Formula:C16H16BrN3OPurity:98% - 99.6%Color and Shape:SolidMolecular weight:346.22DS21360717
CAS:<p>DS21360717 is an effective oral tyrosine kinase inhibitor with anticancer activity and IC50 of 0.49 nM.</p>Formula:C21H23N7OPurity:98%Color and Shape:SolidMolecular weight:389.45EGFR/HER2-IN-2
CAS:<p>EGFR/HER2-IN-2 (Compound ZINC35560729) is a dual EGFR and HER2 inhibitor that acts on both EGFR (IC50: 5.02 μM) and HER2 (IC50: 0.83 μM).</p>Formula:C26H23N5O3Color and Shape:SolidMolecular weight:453.49UNC-CA359
CAS:<p>UNC-CA359: potent EGFR inhibitor, IC50=18 nM, strong anti-tumor effect, promising for chordoma.</p>Formula:C18H14ClN3O2Color and Shape:SolidMolecular weight:339.78CAY10717
CAS:<p>CAY10717 inhibits 34/104 kinases at 100 nM, targets EGFR/ABL/B-Raf mutations, kills various cancer cells, and blocks HUVEC growth.</p>Formula:C29H25F3N6O3Color and Shape:SolidMolecular weight:562.54Cloperastine fendizoate
CAS:<p>Cloperastine fendizoate (Hustazol) inhibits the hERG K+ currents in a concentration-dependent manner (IC50: 27 nM).</p>Formula:C40H38ClNO5Purity:99.97%Color and Shape:SolidMolecular weight:648.19Falnidamol
CAS:<p>Falnidamol (BIBX 1382), an oral selective EGFR inhibitor, IC50 3 nM, weak on ErbB2 and others, anti-cancer pyrimido-pyrimidine.</p>Formula:C18H19ClFN7Purity:98.816%Color and Shape:SolidMolecular weight:387.84A-935142
CAS:<p>A-935142 enhances hERG (Kv 11.1) channels, slows inactivation, promotes activation, and shortens repolarization.</p>Formula:C18H19F3N2O2Purity:98.97% - 99.91%Color and Shape:SolidMolecular weight:352.35EMI1
CAS:<p>EMI1 targets mutated EGFR in drug-resistant NSCLC research.</p>Formula:C20H18N2O3Purity:99.96%Color and Shape:SolidMolecular weight:334.37EGFR-IN-9
CAS:<p>EGFR-IN-9 is a potent EGFR kinase inhibitor with IC50s of 7 nM, 28 nM for the wild type EGFR kinase and double mutant EGFR kinase (L858R/T790M).</p>Formula:C29H24N4O3Purity:99.8%Color and Shape:SolidMolecular weight:476.53Rezivertinib
CAS:<p>Rezivertinib (BPI-7711) is an EGFR inhibitor with antitumor activity and can be used to study central nervous system diseases.</p>Formula:C27H30N6O3Purity:99.26% - 99.89%Color and Shape:SolidMolecular weight:486.57Epitinib succinate
CAS:<p>Epitinib succinate (HMPL-813 succinate) is an orally active and brain penetration EGFR tyrosine kinase inhibitor and can be used in studies about cancer.</p>Formula:C28H32N6O6Purity:98.02% - 99.79%Color and Shape:SolidMolecular weight:548.59Sunvozertinib
CAS:<p>Sunvozertinib (DZD9008) is a potent ErbBs and BTK inhibitor, with inhibitory effects on EGFR, Her2.Cost-effective and quality-assured.</p>Formula:C29H35ClFN7O3Purity:98.11% - 99.63%Color and Shape:SolidMolecular weight:584.08Tyrphostin A25
CAS:<p>Tyrphostin A25 (Tyrphostin AG 82) is a specific EGFR tyrosine kinase inhibitor and GPR35 agonist with an IC50 value of 0.94 μM for GPR35 and an EC50 value of 5.</p>Formula:C10H6N2O3Purity:98.76%Color and Shape:Yellow Green Powder /Off-White SolidMolecular weight:202.17PD 174265
CAS:<p>PD 174265 is an effective, selective and reversible inhibitor of epidermal growth factor receptor (EGFR) with an IC50 of 0.45 nM.</p>Formula:C17H15BrN4OPurity:99.51%Color and Shape:SolidMolecular weight:371.23EGFR-IN-99
CAS:<p>EGFR-IN-99 (JBJ-03-142-02) is an EGFR and HER2 Exon 20 insertion mutation inhibitor for the study of non-small cell lung cancer (NSCLC).</p>Formula:C25H22FN7O3Purity:97.75%Color and Shape:SolidMolecular weight:487.49Larotinib
CAS:<p>Larotinib is an orally active, potent, and broad-spectrum tyrosine kinase inhibitor (TKI) with an IC50 of 0.6 nM for EGFR.</p>Formula:C24H26ClFN4O4Purity:98.45%Color and Shape:SolidMolecular weight:488.94SKLB 1028
CAS:<p>SKLB 1028, an oral EGFR/FLT3/Abl inhibitor, excels in AML and CML with Abl mutations.</p>Formula:C24H29N9Purity:99.90% - >99.99%Color and Shape:SolidMolecular weight:443.55PKI-166
CAS:<p>PKI-166: oral EGF-R tyrosine kinase inhibitor (IC50: 0.7 nM), halts growth & spread of many human cancers, including pancreatic.</p>Formula:C20H18N4OPurity:99.2%Color and Shape:SolidMolecular weight:330.38CGP77675
CAS:<p>CGP77675 (ZINC1488120) is a potent and selective inhibitor of Src family kinase with IC50s of 5-20 and 40 nM for the phosphorylation of peptide substrates and</p>Formula:C26H29N5O2Purity:99.66%Color and Shape:SolidMolecular weight:443.54LY 456236 hydrochloride
CAS:<p>LY 456236 hydrochloride (MPMQ hydrochloride) is an mGlu1 receptor antagonist with an ic50 value of 143 nM.</p>Formula:C16H16ClN3O2Purity:99.95%Color and Shape:SolidMolecular weight:317.77HKI-357
CAS:<p>HKI-357 irreversibly inhibits EGFR/ERBB2 (IC50: 34/33 nM), blocks EGFR Y1068 autophosphorylation, and AKT/MAPK phosphorylation.</p>Formula:C31H29ClFN5O3Purity:99.91%Color and Shape:SolidMolecular weight:574.05EGFR-IN-29
CAS:<p>EGFR-IN-29 is a potent EGFR inhibitor.</p>Formula:C36H46BrN8O2PColor and Shape:SolidMolecular weight:733.68EGFR-IN-30
CAS:<p>EGFR-IN-30 is an EGFR inhibitor (IC50: 1-10 nM, <1 nM WT/mutants) with potential in cancer research.</p>Formula:C28H33BrN7O2PColor and Shape:SolidMolecular weight:610.49Labuxtinib
CAS:<p>Labutinib is a selective inhibitor of the c-kit tyrosine kinase [1].</p>Formula:C20H16FN5O2Purity:99.77%Color and Shape:SolidMolecular weight:377.37EGFR-IN-85
CAS:<p>EGFR-IN-85 (Compound 1), an EGFR inhibitor, exhibits potent activity with an IC50 of 0.19 μM against EGFRvⅢ phosphorylation and can suppress intratumoral EGFR</p>Formula:C26H30N8O2Purity:98%Color and Shape:SolidMolecular weight:486.57BPIQ-I
CAS:<p>BPIQ-I (PD 159121), an ATP-competitive EGFR tyrosine kinase inhibitor, exhibits potent anti-proliferative activity.</p>Formula:C16H12BrN5Color and Shape:SolidMolecular weight:354.2PF-06459988
CAS:<p>PF-06459988 is a novel, effective, orally active, irreversible, and selective epidermal growth factor receptor (EGFR) mutant inhibitor.</p>Formula:C19H22ClN7O3Purity:98%Color and Shape:SolidMolecular weight:431.88(Z)-RG-13022
CAS:<p>(Z)-RG-13022 is a tyrosine kinase (TK) inhibitor that preferentially inhibits the TK activity of the EGF receptor, restricting the EGF-stimulated growth of cultured cells. It demonstrates an IC50 of 11 μM for DNA synthesis in HN5 cells, showcasing thrice the potency of its isomer, (E)-RG-13022 (IC50 = 38 μM). This compound is applied in breast cancer cell research [1] [2].</p>Formula:C16H14N2O2Color and Shape:SolidMolecular weight:266.29EGFR-IN-61
CAS:<p>EGFR-IN-61 inhibits EGFR kinase (IC50: 42 nM L858R/T790M, 137 nM L858R/T790M/C797S, 743 nM WT) and slows A549 & H1975 cell growth (IC50: 2.14 & 1.82 μM).</p>Formula:C33H37ClN8O3Purity:98%Color and Shape:SolidMolecular weight:629.15JGK-068S
CAS:<p>Compound I (JGK-068S) is a potent inhibitor of the epidermal growth factor receptor (EGFR) [1].</p>Formula:C22H23BrFN5O2Purity:98%Color and Shape:SolidMolecular weight:488.35BEBT-109
CAS:<p>BEBT-109 is a selective epidermal growth factor receptor (EGFR) inhibitor that shows anti-tumor activity in EGFR-mutant non-small cell lung cancer.</p>Formula:C27H32N8O3Purity:97.26%Color and Shape:SolidMolecular weight:516.6DZD1516
CAS:<p>DZD1516, a potent and selective HER2 inhibitor (IC50 = 0.56 nM), demonstrates good blood-brain barrier permeability and exhibits antitumor activity in both</p>Formula:C28H27F2N7O3Purity:98%Color and Shape:SolidMolecular weight:547.562′-Thioadenosine
CAS:<p>2'-Thioadenosine (PD157432) serves as a selective and irreversible inhibitor of ErbB-1 and ErbB-2 tyrosine kinases, demonstrating an IC50 value of 45 µM against</p>Formula:C10H13N5O3SPurity:98%Color and Shape:SolidMolecular weight:283.31Lifirafenib
CAS:<p>Lifirafenib (Beigene-283) is a potent inhibitor of RAF family kinases and EGFR in biochemical assays with IC50 of 23, 29 and 495 nM for the recombinant</p>Formula:C25H17F3N4O3Purity:98% - 98.25%Color and Shape:SolidMolecular weight:478.42EGFR-IN-71
CAS:<p>EGFR-IN-71 is a potent inhibitor of epidermal growth factor receptor (EGFR) (IC50= 3.7 μM). EGFR-IN-71 has research value in chordoma.</p>Formula:C16H9ClIN3Color and Shape:SolidMolecular weight:405.62HER2-IN-5
CAS:<p>HER2-IN-5 is an effective inhibitor of orally active HER-2.</p>Formula:C27H33N7O3Color and Shape:SolidMolecular weight:503.6EGFR-IN-32
CAS:<p>EGFR-IN-32, a potent EGFR blocker, shows promise for EGFR-mutated illnesses. (Patent WO2021185297A1, compound 2)</p>Formula:C31H34N6O3Color and Shape:SolidMolecular weight:538.64BGB-102
CAS:<p>BGB-102 (JNJ-26483327) is a kinase inhibitor targeting FLT3 and YES1 and an antagonist targeting EGFR and VEGFR3.</p>Formula:C22H25BrN4O2Purity:99.02%Color and Shape:SolidMolecular weight:457.36EGFR/CSC-IN-1
CAS:<p>EGFR/CSC-IN-1 is a dual inhibitor targeting both the epidermal growth factor receptor (EGFR [IC50 10.52 nM]) and cancer stem cells (CSC), with potential</p>Formula:C54H54Cl2FN7O7S2Purity:98%Color and Shape:SolidMolecular weight:1067.08JND3229
CAS:<p>JND3229 inhibits EGFRC797S; IC50: 5.8-30.5 nM; halts cell growth; effective in non-small cell lung cancer study.</p>Formula:C33H41ClN8O2Purity:98.75%Color and Shape:SolidMolecular weight:617.18EGFR-IN-36
CAS:<p>EGFR-IN-36 inhibits EGFR, HER2, & mutants with IC50s: 19.09 nM (EGFR WT), 120.01 nM (HER2 WT), 2.35 nM (HER2 mutant).</p>Formula:C26H25ClN6O2Color and Shape:SolidMolecular weight:488.97BMS-599626 Hydrochloride
CAS:<p>BMS-599626 HCl (AC480 HCl) is an oral inhibitor of HER1, HER2, HER4 kinases, potentially blocking tumor growth. IC50: 22/32/190 nM.</p>Formula:C27H28ClFN8O3Purity:99.98%Color and Shape:SolidMolecular weight:567.01PAT-505
CAS:<p>PAT-505 is an autologous epidermal growth factor inhibitor.</p>Formula:C23H18ClF2N3O2SPurity:98.84%Color and Shape:SolidMolecular weight:473.92EGFR mutant-IN-1
<p>EGFR mutant-in-1, a 5-methylpyrimidopyridone, selectively inhibits EGFRL858R/T790M/C797S mutants with an IC50 of 27.5 nM, lessening EGFRWT impact.</p>Formula:C34H39ClFN7O2Purity:98%Color and Shape:SolidMolecular weight:632.17
